She left Bank of America to start a fragrance brand with $300. Last year, it made $21 million.
THE SO WHAT
A bootstrapped fragrance brand scaling from $300 to $21m in revenue highlights how much of consumer brand-building has shifted to distribution, community, and narrative over capital. Incumbent CPG and beauty players should assume more niche brands can reach eight figures without institutional backing and adjust acquisition and partnership strategies accordingly.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureSources: Jev developer TypeSafe is in talks to raise $1B+ at a $10B+ valuation; last week the startup announced a $40M seed, PitchBook says at a $200M valuation
A jump from a $200M seed to $10B+ in a week is less about fundamentals and more about capital’s fear of missing the next foundation layer. If you’re an operator, treat Jev as a high-volatility dependency—experiment, but don’t anchor roadmaps on a tool whose funding curve outpaces its production proof.
Startups & VentureHow Is BlackRock’s AI Trade Evolving Beyond Pioneers of the Tech?
If tweaks to BlackRock’s AI-themed ETFs are already redirecting billions, AI exposure is now an asset allocation question, not just a stock-picking story. Public companies should assume investors will benchmark them on explicit AI strategy disclosures and revenue sensitivity to AI indices, not generic “innovation” narratives.
Startups & VentureIsland raises $400m at a $6.4bn valuation to govern AI agents
A $400m Series F at a $6.4bn valuation for an “enterprise browser” framed around governing AI agents says the market is pricing control surfaces, not just models. If you’re deploying agents in the enterprise, budget for a governance and policy layer as a first-class product category, not a feature you bolt onto existing security tools.
The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round
A nearly $800m raise and $15bn valuation for a medical LLM startup shows capital is betting that specialty, workflow-deep models can justify standalone mega-unicorns. Health systems and payers should expect rapid pressure to standardize around a small set of clinical AI platforms and lock in data-sharing terms while leverage is still balanced.